[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368883-105":59,"doc-detail-368883-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","peritoneal-immunosurgery-immunotherapy-augmented-surgery-for-the-treatment-of-peritoneal-cancers","Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers","","Peritoneal malignancy disrupts multiple physiological systems, and the heterogenous origin and dynamic behavior of peritoneal cancer limit the effectiveness of standard guideline-driven approaches. The review explains how successful care must address underlying pathology, coordinate systemic responses to surgical interventions, and target immune perturbations that enable establishment and propagation of this multifaceted disease. It evaluates cancer immunotherapy strategies and the rationale for combining immunotherapy with surgery to enhance durable anti-cancer immune outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/peritoneal-immunosurgery-immunotherapy-augmented-surgery-for-the-treatment-of-peritoneal-cancers/368883/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/peritoneal-immunosurgery-immunotherapy-augmented-surgery-for-the-treatment-of-peritoneal-cancers/368883.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is treating peritoneal cancer difficult with standard approaches?","Question",{"text":112,"@type":113},"Peritoneal malignancy involves disruptions across multiple physiological systems, with heterogenous origins and dynamic disease behavior. These factors make guideline-based standard approaches less effective.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What immune-focused goal underlies cancer immunotherapy in this review?",{"text":117,"@type":113},"Cancer immunotherapy aims to harness immune responses to attack malignancy and establish durable memory responses that can reduce recurrence risk.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review connect surgery with immunotherapy for peritoneal cancer?",{"text":121,"@type":113},"The review outlines a rationale for integrating immunotherapy with surgery to overcome challenges posed by the dynamic, multifaceted nature of peritoneal disease and to improve eradication strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368883,1790826495,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Journal of  \nSurgical Oncology  \nREVIEW ARTICLE   \nPeritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers  \nAda I. Ozcan1  | Arianexys Aquino López1,2 | Mary K. McKenna1,3,4 | Malcolm K. Brenner1,4 | Alastair M. Thompson5  \n1Center for Cell Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA | 2Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA | 3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA | 4Department of Medicine, Baylor College of Medicine, Houston, TX, USA | 5Department of Surgical Oncology, Baylor College of Medicine, Houston, TX, USA  \nCorrespondence: Ada I. Ozcan ([adairmakozcan@gmail.com](adairmakozcan@gmail.com)) | Alastair M. Thompson ([alastair.thompson@bcm.edu](alastair.thompson@bcm.edu))  \nReceived: 3 September 2024 | Revised: 2 July 2025 | Accepted: 30 July 2025  \nKeywords: immunotherapy | peri‐operative immunity | peritoneal cancer | peritoneum | surgery  \n\n| ABSTRACT\u003Cbr>Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that fit into guidelines. We describe how successful treatment should address the underlying pathology, the systemic response to surgical treatments and target the immune perturbations that facilitate the establishment and propagation of this multifaceted disease. |  |\n| --- | --- |\n| Cancer immunotherapy harnesses the immune system to mount | the immune system to assess and respond to these differing |\n| therapeutic responses against malignancy with a subsequent goal of | needs. Multifaceted treatment protocols incorporating immu- |\n| establishing a memory response that can prevent recurrences [1, 2]. | notherapy, when combined with surgery, hold promise for |\n| To establish durable immune responses against cancer, we can use | overcoming the challenges we currently face in treating this |\n| drugs, antibodies, toxins, vaccines, and viruses that engage the | dynamic disease [2, 12] . in this review we assess the current |\n| immune system against cancer, or employ adoptive cellular thera- | status of PMD treatment, outline the rationale for integrating |\n| pies to target cancer in ways unavailable to the natural immune | immunotherapy with surgery to eradicate PMD, and consider |\n| system [3]. Current therapeutic approaches include: inducing tumor cell death through monoclonal antibodies against tumor‐associated antigens; supporting innate and adaptive immunity with checkpoint | the associated challenges. |\n| antibodies, vaccines, or cytokines, and utilizing oncolytic virotherapy [4–6]. Adoptive cellular therapies equip patients with immune cells, natural or engineered, that can replace or even | 1 | PMD Pathophysiology |\n| outperform endogenous immune effector mechanisms that would | PMD has a significantly higher incidence than primary perito- |\n| fail to produce a sufficient antitumor response [7]. For greater | neal malignancy, arising most commonly from ovarian, colo- |\n| specificity and efficacy, these immunotherapeutics can be comple- | rectal, pancreatic, or gastric cancers [9, 13, 14] . The anatomy |\n| mented with custom‐designed delivery methods [8]. | that allows wide access to critical abdominal organs, the plasticity of the mesothelial cells, and the supportive nature of the |\n| Peritoneal metastatic disease (PMD) often signifies dissemi- | submesothelium contrasted with its low capillary density are |\n| nated disease spanning multiple anatomic compartments, each | some of the features that have been proposed to contribute to |\n| of which may respond differently to conventional treatments | peritoneal cancer progression in the face of systemic treatments |\n| [9–11] . Effective treatment of PMD requires the recruitment of | [13, 15] . |","cbCaitvu2L2N8mgJ","https://ap.wps.com/l/cbCaitvu2L2N8mgJ","pdf",951127,21,"English","# Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers\n## PMD Pathophysiology\n## Cancer Immunotherapy Strategies\n## Integrating Immunotherapy With Surgery","[{\"question\":\"Why is treating peritoneal cancer difficult with standard approaches?\",\"answer\":\"Peritoneal malignancy involves disruptions across multiple physiological systems, with heterogenous origins and dynamic disease behavior. These factors make guideline-based standard approaches less effective.\"},{\"question\":\"What immune-focused goal underlies cancer immunotherapy in this review?\",\"answer\":\"Cancer immunotherapy aims to harness immune responses to attack malignancy and establish durable memory responses that can reduce recurrence risk.\"},{\"question\":\"How does the review connect surgery with immunotherapy for peritoneal cancer?\",\"answer\":\"The review outlines a rationale for integrating immunotherapy with surgery to overcome challenges posed by the dynamic, multifaceted nature of peritoneal disease and to improve eradication strategies.\"}]","Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers | PDF",1790179067,53]